KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

CT-P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, Active-Controlled, Phase 3 Study.

Sarbjit S Saini, Marcus Maurer, Yevgeniya Dytyatkovska, Ewa Springer, Maria Ratkova, Borislava Krusheva, Chun Wook Park, Grazyna Pulka, Marta Chełmińska, Adam Reich, Sunghyun Kim, Keumyoung Ahn, Suyoung Kim, Sewon Lee, Jieun Ka, Jongho Kim, Clive Grattan

Allergy 80(8) 2167-2177

PMID39785096
PMCIDPMC12368742
DOI10.1111/all.16446
发表日期2025-01-09
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other。
摘要

摘要

BACKGROUND: This study compared the therapeutic equivalence of CT-P39 (an omalizumab biosimilar) and EU-approved reference omalizumab (ref-OMA) in patients with chronic spontaneous urticaria. METHODS: This double-blind, randomized, active-controlled Phase 3 study (NCT04426890) included two 12-week treatment periods (TPs). In TP1, patients received CT-P39 300 mg, ref-OMA 300 mg, CT-P39 150 mg, or ref-OMA 150 mg. In TP2, patients treated with ref-OMA 300 mg were rerandomized to CT-P39 300 mg or ref-OMA 300 mg; patients initially randomized to CT-P39 300 mg continued this regimen; and patients initially randomized to CT-P39 or ref-OMA 150 mg received 300 mg dosing with the same drug. The primary endpoint for the assessment of therapeutic equivalence of CT-P39 300 mg and ref-OMA 300 mg was change from baseline in weekly itch severity score (ISS7) at week 12. RESULTS: In TP1, 619 patients were randomized (CT-P39 300 mg, n = 204; ref-OMA 300 mg, n = 205; CT-P39 150 mg, n = 107; ref-OMA 150 mg, n = 103). Equivalence was demonstrated between CT-P39 300 mg and ref-OMA 300 mg for mean change from baseline in ISS7 at week 12; confidence intervals (CIs) were within predefined equivalence margins: global analysis: treatment difference 0.77, 95% CI -0.37 to 1.90; US analysis: treatment difference 0.70, 90% CI -0.22 to 1.63. The proportion of patients experiencing ≥ 1 treatment-related adverse event was comparable across groups. Secondary efficacy, quality of life, pharmacokinetic, safety, and immunogenicity outcomes were comparable between groups at a given dose level, with no evident impact of switching. CONCLUSIONS: Equivalent efficacy was observed between CT-P39 and ref-OMA, with comparable safety also evident.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Patient disposition. EU, European Union; GCP, good clinical practice; ref‐OMA, EU‐approved reference omalizumab; TP1, treatment period 1; TP2, treatment period 2. † This includes screening failures and randomized patients including GCP non‐compliant sites. ‡ One patient was randomized by mistake and discontinued the study before the first study drug administration. § One patient who underwent the second‐randomization, but discontinued before the first study drug administration in TP2 was counted as discontinuing treatment in TP1; however, in line with all the other groups, the proportion of patients completing TP2 in this group is based on the number of randomized patients.
非 KM Figure
FIGURE 2FIGURE 2 (A and B) Mean (±SD) change from baseline in ISS7 and (C and D) HSS7 in TP1 (mITT set) and TP2 (mITT TP2 set). EU, European Union; HSS7, weekly hives severity score; ISS7; weekly itch severity score; mITT, modified intention‐to‐treat; ref‐OMA, EU‐approved reference omalizumab; SD, standard deviation; TP1, treatment period 1; TP2, treatment period 2.
非 KM Figure